PAVmed
PAVM
5 hedge funds and large institutions have $243K invested in PAVmed in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
22% less capital invested
Capital invested by funds: $312K → $243K (-$69K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
+$59.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
-$45.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCS
1
Levin Capital Strategies
New York
| $112K | – | – | – |
|
|
MSAM
2
Moloney Securities Asset Management
Manchester,
Missouri
| $73K | -$45.8K | -17 | -35% |
|
|
3
Brown Advisory
Baltimore,
Maryland
| $50K | +$59.3K | +22 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $5K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $2K | +$2.69K | +1 | New |
|
6
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
PAVM Hedge Fund Activity: Q1 2017 in Review
5 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q1 2017, worth a combined $243K — down 22% from $312K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PAVM positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Brown Advisory, opening a new position worth an estimated $59.3K. The largest seller was Moloney Securities Asset Management, cutting an estimated $45.8K.
- 5 institutional investors held PAVmed (PAVM) as of Q1 2017, up from 3 in Q4 2016.
- Funds reported $243K of PAVmed stock for Q1 2017, down 22% quarter-over-quarter.
- 2 funds opened new PAVmed positions in Q1 2017 and 0 closed out, a net change of +2 holders.
- The largest PAVmed buyer in Q1 2017 was Brown Advisory, an estimated $59.3K added.
- The largest PAVmed seller in Q1 2017 was Moloney Securities Asset Management, an estimated $45.8K sold.
Based on aggregated 13F filings for Q1 2017.